Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on

New Human Clinical Studies Will Investigate the Role of NIAGEN® Nicotinamide Riboside in Mitochondrial Biogenesis and Systolic Heart Failure

IRVINE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that two new collaborative human clinical studies on NIAGEN® Nicotinamide Riboside (NR) have registered and are now underway at the University of Cambridge and the University of Washington.

ChromaDex Co-Founder and CEO, Frank Jaksch, commented, “With nearly 140 collaborative agreements in place, we continue to shape the landscape of NR and NAD research, ensuring that each study helps to quantify the value of NIAGEN® and its role in human health.”

The University of Cambridge research team will study 15 patients with mitochondrial disease to determine whether NIAGEN® induces mitochondrial biogenesis and affects mitochondrial function in patients with mitochondrial myopathy. This trial is expected to complete in late Spring, 2019.

The second study, at the University of Washington, will include 30 patients with clinically stable, systolic heart failure. The research team primarily aims to assess the safety and tolerability of NIAGEN® in this high-risk population. The team will also collect exploratory data on the effects of NIAGEN® on cardiovascular functional capacity in these patients. Registration of the study quickly follows publication of their last human clinical trial  which published early December, 2017.  This latest study is currently expected to complete at the end of June, 2018.

“By offering clinical study products at no cost for double-blind, placebo controlled independent research, we are enabling the next phase of research in humans, and in at-risk populations where NIAGEN® has the potential to improve quality of life.  Most of these major human investigations are funded by national research funding bodies and other research organizations unrelated to ChromaDex which attests to the promising future of NIAGEN®,” Robert N. Fried, President and Chief Operating Officer of ChromaDex shared.

ChromaDex has enabled global NIAGEN® research in a diverse set of health-related fields by providing their safety-verified, NIAGEN® at no cost to independent investigators who are leading nearly 140 programs in 34 different areas of health research including brain health, Alzheimer’s and cognitive support, heart health, and inflammation. To date there are 3 published clinical trials of NIAGEN® and NIAGEN® is being studied in at least 13 of the 16 human trials currently registered on

For more information on ChromaDex, visit

About NAD
NAD activates cellular metabolism and energy production within the cell’s “power stations,” the mitochondria. Our mitochondria are constantly working to convert the food into the energy necessary to power all bodily systems as well as help us stay healthy enough to ward off illness. The challenge is that both NAD levels and mitochondrial functions decline as we age. This reduction in NAD is believed by scientists to be linked to a wide variety of age-related diseases and conditions.  For more information on NAD, visit

About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. To learn more about ChromaDex, please visit

Forward-Looking Statements:
This release contains forward-looking statements relating to ChromaDex and ChromaDex’s business within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the clinical studies and potential of NIAGEN® to improve quality of life. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. 

ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing